Fig. 3From: Therapy development for spinal muscular atrophy: perspectives for muscular dystrophies and neurodegenerative disordersTimeline of the current Onasemnogene abeparvovec/Zolgensmaâ„¢ trials. Illustration of the different clinical trials (clinical trials 1 and 3, LFTU) with Onasemnogene abeparvovec/Zolgensmaâ„¢ according to their scheduled durationBack to article page